Oxaide sample — Open brief • Private research desk • brief@oxaide.com • UEN 201806463W • Research, not advice

FINDINGS — SingPost supplemental dividend verification (REF SAMPLE-open, 28 Sep 2026)
One line per finding: location + issue + fix. All figures verified against pages read this session.

1. ANSWER.md / Verdict — risk of confusing FY24/25 9.00c special with FY25/26 0.41c supplemental — FIXED: both identified by year, amount, funding source, and pay date in verification table (SGX notice 24 Jun 2026 + SingPost results release 14 May 2026).
2. Secondary source (Singaporean Investor, 25 Jun 2026) states underlying net profit "S$10.1 million" — CONFLICTS with official S$10.7m (results release + AR highlights) — FIX: used S$10.7m; blog figure excluded from brief.
3. Secondary source (Singaporean Investor) mislabels S$38.1m write-back as "aged trade receivables … unclaimed over 7 years" and elsewhere as "trade payables (S$10.7m)" — CONFLICTS with official "derecognition of aged trade payables S$38.1m" — FIX: used official wording and figure; blog wording excluded.
4. Secondary source (Beansprout FY26, 21 Jul 2026) states "ex-dividend date … 3 August 2026" — CONFLICTS with SGX notice (Ex 31/07/2026, Record 03/08/2026) — FIX: brief uses SGX ex/record dates; Beansprout date treated as record-date conflation, excluded.
5. Prior-year special total reported as both S$202.5m and S$202.6m across sources — MINOR variance (rounding/cash-flow read) — FIX: brief shows "~S$202.5m" for the declared special and "S$202.6m" only where citing Beansprout's financing-cash-flow line.
6. ANSWER.md / Honest limits — net-of-tax derecognition amount not disclosed in releases read — FLAGGED in-brief: S$9.3m presented as board's chosen distribution, not the full net gain. No fix possible from public releases.
7. ANSWER.md / Cash walk — ordinary total ~S$3.2m and ~30% payout are DERIVED (0.14c × ~2.26bn shares), not company-published totals — FIX: marked "(approx, derived)" wherever shown.
8. S&P bulletin PDF (SGXAnn_S&P's_Bulletin_on_Singapore_Post_2026.05.15.pdf) returned a 404 (page not found) on fetch — OMITTED as source; no snippet content used. No fix needed; claim coverage complete without it.
9. Banned-word / house-style sweep of ANSWER.md — PASS: no Oxaide prices, products, upsells, or in-body contact addresses; footer "Oxaide • UEN 201806463W • Research, not advice • REF SAMPLE-open" present; header+footer carry ILLUSTRATIVE SAMPLE — REAL PUBLIC FINDINGS — NOT COMMISSIONED.

Oxaide • UEN 201806463W • Research, not advice • REF SAMPLE-open

---
ILLUSTRATIVE SAMPLE — real public findings, not commissioned. Research, not advice. Oxaide UEN 201806463W • brief@oxaide.com
